Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma
What is the purpose of this trial?
The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.
- Trial withYale University
- Start Date02/21/2022
- End Date08/01/2023
- Last Updated11/11/2022
- Study HIC#2000028918